Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
Latest Information Update: 18 Aug 2026
At a glance
- Drugs 64Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Acronyms Co-PSMA
Most Recent Events
- 14 Aug 2026 Status changed from active, no longer recruiting to completed.
- 31 Mar 2026 According to a Clarity pharmaceuticals media release, results from the Co-PSMA trial published in European Urology, the official journal of the European Association of Urology (EAU) Congress 2026.
- 31 Mar 2026 Results presented in the Clarity pharmaceuticals Media Release.